Map Unavailable

Date/Time
Date(s) - 06/16/2020 - 06/17/2020
1:00 pm - 4:30 pm CET

Categories

*** VIRTUAL TRAINING ***

 

The chemical and physical characterization of materials and devices has long been considered an important step in evaluating biological safety. The most recent revisions of ISO 10993-1:2018 and ISO 19003-18:2020 continue to emphasize the importance of this evaluation and potential testing needs.

As global regulatory bodies adjust to applying the new ISO 10993-18: 2020, manufacturers must  understand the potential nuances of this new  regulation. . For example, EU Notified Bodies may require additional evaluation as the Medical Device Regulation (MDR) looms closer, while the U.S. Food & Drug Administration (FDA) has placed an increased emphasis on characterization and requests very specific requirements as outlined in the 2016 guidance document (while continuing to expand the use of the analytical data). The successful implementation of this standard, and evaluation outlined in supporting documents, is critical for medical device manufacturers if they wish to stay on track with  market clearance plans.

In these online sessions, NAMSA will discuss the chemical characterization of materials and the evaluation steps to choose proper tests, extracts and test duration to meet the latest industry requirements. This workshop, split over two (2) half days, will include instruction via our virtual training platform, as well as multiple hands-on exercises guided by an experienced NAMSA instructor.

Upon completion, attendees will be able to:

  • Relate ISO 10993-18:2020 to ISO 10993-1 and the biological evaluation of devices
  • Discuss the changes in the new document in a practical use format
  • Discuss how material and chemical characterization fit into the MDR
  • Develop a testing strategy for multiple devices
  • Solve problems that might come about in a testing situation such as a degraded sample or liquid test article
  • Plan for future testing needs of materials and finished medical devices

Who Should Attend?

  • Regulatory Affairs and Quality Assurance Professionals
  • Research, Design and Manufacturing Engineers
  • Microbiologists and Chemists involved in the evaluation of Medical Devices
  • Product Managers, Laboratory Managers
  • Process Development and System Engineers
  • Toxicologists and Biological Safety Specialists
  • Testing professionals that  require continuing education for RAPS Certification
  • Attendees of  NAMSA Course A or B and desire more hands-on experience with chemical characterization

Pricing:

Early Registration through 22 May 2020: 403€ ($450 USD)
Regular Registration beginning 23 May 2020: 493€ ($550 USD)

Event Details

If making a credit card payment, note that your profile address must match the credit card address on file.
Ticket Type Price Spaces
Registration $ 550.00

Please enter your credit card information below

/

By choosing to submit your information to register for this event, you are providing information to NAMSA that will allow you to receive email alerts to stay informed on industry updates and be directly contacted by NAMSA regarding our services.

At any time, you can submit a request to withdraw your consent for the use of information provided by you by emailing communications@namsa.com. For additional information, please visit our Privacy Policy or contact us at privacy@namsa.com.

NAMSA uses a third-party provider, CyberSource, to process payment when you register for NAMSA's Training Services. For information related to CyberSource's privacy policy and use of that information, please contact CyberSource directly.


16 June  13:00-13:15: Introduction 13:15-14:30: Overview of ISO 10993-18 13:15-14:30 14:30 -14:45: Q&A 14:45-15:00: Break 15:00-16:00: Workshop 16:00 -16:30: Questions 17 June  13:00 -14:30: Tests to Consider 14:30 -14:45: Q&A 14:45-15:00: Break 15:00-16:00: Workshop 16:00 -16:30: Questions
  Don Pohl, Principal Product Development Strategist, holds a Bachelor’s degree from Ohio State University. Don has over 25 years of experience in the preclinical evaluation of medical devices for biological safety. During his career, he has held a variety of positions ranging from laboratory supervision/management, GLP Study Director, Technical Specialist for Laboratory Information Management System, Technical Specialist and project manager for Biological safety and biological risk assessment consultation. He has specific expertise in the evaluation process outlined in ISO 10993-1 as well as the expectations of the USFDA and other countries in their interpretation of the biological safety evaluation of medical devices.